#Japan #Tokyo #Simplex Quantum #NIHA-HF #MedTech Innovator

Simplex Quantum Selected for MedTech Innovator Asia Pacific 2025 Accelerator

Simplex Quantum, a groundbreaking medical technology startup located in Tokyo, has made waves by being selected for the prestigious MedTech Innovator Asia Pacific 2025 Accelerator Program. This selection signifies recognition among the top 20 promising startups, championing advancements in the medical technology sector.

The MedTech Innovator program, renowned as the world's premier accelerator for medical technology enterprises, operates with the goal of enhancing human health by nurturing companies that revolutionize patient care. In its Asia-Pacific iteration, the program links innovative startups with investors, industry leaders, and service professionals within the medical technology field. This collaboration aims to expedite the commercialization of transformative healthcare technologies in the region.

This year marked a record-breaking interest, with over 550 companies applying for the program. Following an extensive selection process, 60 companies were invited to pitch their solutions, with only 20 making it to the cohort for 2025. These handpicked companies will engage in a four-month accelerator experience, culminating in a showcase event and grand finals in Singapore at the end of October.

Ryu Saito, the CEO of Simplex Quantum, expressed the company’s enthusiasm, stating, "We are honored to be part of the MedTech Innovator Asia Pacific 2025 cohort. This opportunity validates our commitment to transforming heart failure detection and management with scalable, AI-driven solutions. We look forward to leveraging this platform to forge strategic partnerships and expand our impact across Asia and beyond."

Revolutionizing Heart Failure Detection with AI

At the heart of Simplex Quantum's innovation is its flagship technology, the NIHA-HF (Neural Intelligent Heart Analyzer – Heart Failure). This cutting-edge solution allows for the early detection of heart failure through a rapid 30-second single-lead ECG, analyzed using advanced neural network algorithms. Traditional detection methods often require expensive imaging technologies or invasive procedures. In contrast, NIHA-HF is intended for integration with standard 12-lead ECG systems and is also accessible through consumer wearable devices.

With patents granted in Japan, the United States, and India, NIHA-HF is currently navigating the regulatory landscape in both Japan (under the PMDA) and the U.S. (from the FDA). It's noteworthy that NIHA-HF remains an investigational device, awaiting formal approval from these regulatory bodies.

About Simplex Quantum

Based in Tokyo, Simplex Quantum dedicates itself to pioneering advancements in cardiovascular care through the application of state-of-the-art machine learning technologies. The company’s flagship product, NIHA-HF, employs proprietary deep learning algorithms to analyze ECG data, facilitating the high-precision detection and monitoring of heart failure conditions. This ambitious endeavor includes collaborations with academic and clinical institutions worldwide to promote proactive and personalized management of heart health.

For more information, visit their official website.

Media Contact:
Moe Kawai
Phone: +81 3-6450-3600
Email: [email protected]

Simplex Quantum’s participation in the MedTech Innovator Asia Pacific 2025 Accelerator positions it at the forefront of medtech innovation, reflecting its commitment to harnessing AI in the quest for better heart health solutions.